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Introduction
With the aim to contribute to the assessment
of the effectiveness of chest x-ray (CXR) screen-
ing for lung cancer (LC), during the 1997-2006
period we carried out an observational study of
CXR screening on a clearly defined population-
based cohort. This project was coordinated by the
Center for Thoracic Surgery of the University of
Insubria, Varese, Italy and was funded by Non-
Profit Organizations. The study was approved by
the Varese Hospital and Health District Ethics
Committee and was registered under the registra-
tion code: ISRCTN90639073. The study cohort,
consisting of 5,815 smokers all from the Varese
Province, was invited to undergo a free-of-charge
programme of annual CXR screenings over a pe-
riod of 5 years, and was recruited by 50 general
practitioners and physicians from a population of
about 60,000 adult residents from the greater
Varese provincial area. The entire invited cohort
received National Health Service (NHS) usual
care, with the addition of CXRs on the screening
participants (21% of the invitees), according to
the previously described protocol [1]. At the end
of the screening programme, a total of 245 LCs
were found out of the entire screening cohort (67
in participants, 178 in non-participants), of which
34 were screen-detected [1]. The LC standardized
mortality ratio (SMR), for the entire screening-
invited cohort, was of 0.82, indicating in the co-
hort a LC mortality reduction of 18%, and 38
fewer LC deaths over the study period [2]. This is
a relatively small benefit, however it could save
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ABSTRACT: Cost of a population-based programme of
chest x-ray screening for lung cancer. L. Dominioni, N.
Rotolo, A. Poli, M. Castiglioni, M. Mangini, M. Spagnoletti,
M. Paolucci, A. Paddeu, W. Mantovani, A. Zanini, A.
Imperatori.
Background. After the implementation of a popula-
tion-based programme of chest x-ray (CXR) screening on
smokers in Varese, Italy, lung cancer (LC) mortality was
significantly reduced. Analysis of the incremental costs
due to this type of screening programme is needed to eval-
uate its economic impact on the healthcare system.
Methods. In July 1997 a population-based cohort,
consisting of all high-risk smokers (n=5,815) identified
among 60,000 adult residents from the Varese province,
was invited to a LC screening programme (an annual
CXR for five years) in a general practice setting, and was
observed through 2006. Invitees received National Health
Service (NHS) usual care, with the addition of CXRs in
screening participants. At the end of observation, among
the 245 LCs diagnosed in the entire screening-invited co-
hort the observed LC deaths were 38 fewer than expect-
ed. To estimate the incremental direct cost due to screen-
ing in the invited cohort for the period July 1997-2006, we
compared the direct cost of screening administration,
CXR screens and LC management in the invited cohort
and in the uninvited and unscreened controls in NHS
usual care setting.
Results. Over the 9.5 years, the total incremental direct
healthcare costs (including screening organization/admin-
istration, CXR screens, additional procedures prompted
by false-positive tests, overdiagnosed LCs) were estimated
to range from € 607,440 to € 618,370 (in euros as of 2012),
equating to between € 15,985- € 16,273 per patient out of
the 38 LC deaths averted.
Conclusions. In a general practice setting, the incre-
mental cost for a CXR screening programme targeted at
all high-risk smokers in a population of 60,000 adults was
estimated to be about € 65,000 per annum, approx. € 16,000
for each LC death averted.
Monaldi Arch Chest Dis 2013; 79: 2, 67-72.
68
L. DOMINIONI ET AL.
many lives, especially given the high incidence of
LC worldwide and the potentially wide applica-
bility of CXR screening. In order to explore the
NHS budget impact of a population-based LC
screening intervention, it is necessary to evaluate
the direct costs involved, the benefits as well as
the harms. Here we describe the economic evalu-
ation of the annual CXR screening programme
we carried out in the Varese province in a gener-
al practice setting.
Methods
We aimed to evaluate the incremental costs at-
tributable to the programme of CXR screening for
LC which we performed from July 1997 through
December 2006. To this effect, over the 9.5-year
duration of the screening programme we analyzed
the total direct costs of CXR screening and LC
management in the screening-invited cohort, and
compared it with the total direct cost of LC man-
agement in a control group of patients observed in
the general population of the same area in the ab-
sence of screening.
Throughout this paper the values of healthcare
services, procedures and interventions were re-
ported in Euros as of the year 2002, the central
year of our screening study (tables 1-3). These val-
ues were estimated based on the 2002 Tariff of
Lombardy Regional Bulletin and on data provided
by the Oncology, Radiotherapy and Palliative Care
Units at the Varese Ospedale di Circolo. For a
more direct comparison with the most recently
published literature, the incremental costs incurred
with screening were expressed in terms of Euros as
of 2012.
Cost of the screening programme
Computation of direct costs attributable to the
screening programme included: a) the cost of or-
ganization and administration; b) the cost of CXR
Table 2. - Cost of treatment of lung cancer (LC)
Components of cost Cost in Euros*
Chest surgery
Operating room occupancy 
(average 3 hours) 1,165.00 - 2,331.00 
Operating room materials 388.00 - 1,165.00
Hospital stay in surgical unit 
(average 12 days) 5,827.00
SUB-TOTAL 7,380.00 - 9,323.00
Chemotherapy for LC stage III
6 cycles (Cisplatin + Gemcitabine) 4,177.00
SUB-TOTAL 4,177.00
Chemotherapy for LC stage IV
3 cycles (Cisplatin + Gemcitabine) 2,089.00
SUB-TOTAL 2,089.00
Palliative radiotherapy
Radiotherapy 2,405.00 - 3,385.00
SUB-TOTAL 2,405.00 - 3,385.00
Radical radiotherapy
Radiotherapy (50-60 Gy) 2,405.00 - 6,974.00
SUB-TOTAL 2,405.00 - 6,974.00
Chemo-Radiotherapy combined
Chemotherapy 2,089.00 - 4,177.00
Radiotherapy 2,405.00 - 6,974.00
SUB-TOTAL 4,494.00 - 11,151.00
Supportive/palliative therapy
Oxygen 397.44
Drugs (analgesics, antibiotics, steroids) 699,00
Hospital stay 1,040.00
SUB-TOTAL 2,136.00
Terminal phase
Cumulative cost of 1 month 1,399.00
SUB-TOTAL 1,399.00
LC: lung cancer.
* Cost in Euros 2002.
Table 1. - Cost of diagnosis and staging of lung cancer
(LC)
Components of cost Cost in Euros*
Screening
CXR exam, dual projection 15.49
SUB-TOTAL 15.49
Cyto-/histologic confirmation of LC
Bronchoscopy with biopsy 180.76
Cytology of sputum/pleural fluid 26.86
CT-guided fine needle aspirate 
and cytology 157.52
Hospital stay 624.00
SUB-TOTAL 989.14
Staging of LC patient stage I-IV
Blood cells count, chemistry, 
tumor markers, arterial gases 117.25
EKG 11.36
CXR exam, dual projection 15.49
CT total body with contrast 482.37
Bone scintigraphy 80.57
Spirometry 23.24
Hospital stay 4,160.00
SUB-TOTAL 4,890.28
Staging of patient unfit 
for active treatment
Blood cells count, chemistry, 
tumor markers, arterial gases 117.25
EKG 11.36
CXR exam, dual projection 15.49
CT total body with contrast 482.37
Hospital stay 2,496.00
SUB-TOTAL 3,122.47
CT: computed tomography. CXR: chest x-ray. EKG: electro-
cardiogram. LC: lung cancer.
* Cost in Euros 2002.
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screenings; c) the cost of additional procedures
prompted by false-positive tests. Moreover, we
considered the direct cost of overdiagnosed LCs,
which was based on the estimate that in the Mayo
Lung Project approximately 5% of screen-detected
LCs were overdiagnosed [3].
Cost of LC management on the screening-invited
cohort
For each of the 245 LC cases that were diag-
nosed overall in the cohort [1], we computed all
healthcare costs for LC management, from the time
of diagnosis until the time of death. For subjects still
alive at the end of study, the computation of costs
was truncated at the study cut off, on December 31,
2006. Briefly, to calculate the total cost of each LC
case in the cohort, costs related to LC diagnosis,
staging, treatment and follow-up procedures (tables
1-3) that were individually incurred were included,
stratified by stage, histology (non-small cell lung
cancer, small cell lung cancer) and treatment
(surgery, chemotherapy, radiation). To determine
the price of the component services, we considered
the phase of care and the frequency of cost-generat-
ing follow-up procedures for each case. For compo-
nents with little variability of cost in the various dif-
ferent NHS facilities throughout the Varese
province, the average cost was indicated; if the
overall cost was considerably variable, the lowest
value and the highest value were taken (tables 1-3).
Cost of LC management in the control group
As a control group we used a previously de-
scribed group of 156 uninvited and unscreened
LC patients diagnosed during the 2000 calendar
year in the Varese district area, who possessed
the necessary screening criteria [1]. Over the 9.5-
year timeframe we computed the total direct cost
of healthcare procedures and interventions (ta-
bles 1-3) incurred for LC management for these
156 control group patients, who received the
NHS usual standard of care in the absence of
screening.
Results
Cost of the screening programme
The total direct cost of the screening pro-
gramme over the 9.5-year period from July 1997
through December 2006 was estimated to range
from € 390,934 to € 394,042 (table 4), after adding
up the cost components a), b), c), as follows:
a) Organization and administration
The general expenses incurred for the initial
organization of the screening programme com-
prised: office supplies; printed recruitment
forms and brochures; mailing of screening invi-
tation letters; advertising of screening with
posters and announcements in local newspapers,
radio and TV; purchase of personal computers to
store CXR readings in the 7 NHS radiologic
centers collaborating in the project; dedicated
software for database in the project main office.
Cost of programme administration included:
part-time secretary; office utilities and material
supplies; staff meetings. Total cost of organiza-
tion and administration over the 9.5 years was €
242,632.
Table 3. Cost of follow-up after treatment of lung
cancer (LC)
Components of cost Cost in Euros*
First year of follow-up
3 Visits 58.00
2 CXR exam, dual projection 30.98
2 Blood cells count, chemistry, 
tumor markers, arterial gases 234.50
1 Chest CT with contrast 161.13
SUB-TOTAL 484.61
Second year of follow-up
2 Visits 38.00
1 CXR exam, dual projection 15.49
2 Blood cells count, chemistry, 
tumor markers, arterial gases 234.50
1 Chest CT with contrast 161.13
SUB-TOTAL 449.12
Third and subsequent years 
of follow-up
2 Visits 38.00
1 Blood cells count, chemistry, 
tumor markers, arterial gases 117.25
1 Chest CT with contrast 161.13
SUB-TOTAL 316.38
CT: computed tomography. CXR: chest x-ray. LC: lung
cancer.
* Cost in Euros 2002.
Table 4. - Cost of screening programme, period July
1997 - December 2006
Components of cost Cost in Euros*
Organization and administration 242,632
Total cost of CXR (5,581 screens) 86,450
Additional procedures prompted 
by screening
• Chest CT with contrast 
(190 false positives) 30,615
• CT-guided fine needle biopsy 
(1 subject) 157
• Thoracoscopic lung wedge biopsy 
(8 subjects)* 31,080 - 34,188
Total* 390,934 - 394,042
CT: computed tomography. CXR: chest x-ray.
* Lowest and highest value of estimated cost, in Euros 2002.
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b) CXR screens
Total expenditure for the 5,581 screening tests
performed on the screening participants (baseline,
n=1,244; annual screens, n=4,337) was € 86,450.
c) Additional procedures prompted by screening
Uncertain or false-positive tests [1] prompted
the following additional investigations: 190 chest
computed tomography (CT) exams with contrast;
one fine-needle aspirate cytology of lung; 8 thora-
coscopic lung wedge resections for biopsy. The to-
tal cost of these additional procedures, none of
which caused severe complications, ranged from
€ 61,852 to € 64,960.
Cost of LC management in the screening-invited
cohort
The total direct cost incurred for healthcare of
all LC cases diagnosed in participants and in non-
participants of the invited cohort is shown in table
5, with the indication of the lowest and highest val-
ue of services. The total direct cost of all 245 LC
cases of the screening-invited cohort ranged from
€ 2,959,155 to € 3,324,662 (table 5). The latter
cost will subsequently be compared in table 5 with
the total direct cost of only 243 LCs of the control
group, as 2 LCs in the invited cohort were likely to
have been overdiagnosed (see below).
Overdiagnosed LCs
As 34 LCs were screen-detected in our screen-
ing programme [1], we approximated that 2 LCs
(5%) had been overdiagnosed. Accordingly during
the calculation of the incremental costs of screen-
ing, to account for overdiagnosed LCs, the total di-
rect cost of only 243 control group LCs will be sub-
tracted from the cost of the 245 LCs from the
screening-invited cohort (see calculation in table 5).
Total cost of screening and LC management in
the screening-invited cohort
The cost of the screening programme added to
the cost of LC management of all 245 cases in the
screening-invited cohort totaled between €
3,350,089 and € 3,718,704 (computation shown in
table 5).
Cost of LC management in the control group
The mean direct cost of LC management for
each patient of the control group was estimated to
range from € 11,809 to € 13,361, implying a total
expenditure ranging from € 2,869,615 to €
3,246,723 for the 243 LCs from the control group
(table 5). The total cost of LC management was
slightly lower in the control group compared to the
invited cohort, as in the latter there were 2 over-
diagnosed cases treated and higher number of
stage I surgically treated patients (table 5).
Incremental costs of LC management including
screening
In the invited cohort the cumulative incremen-
tal costs of LC management, including screening,
was estimated to range between € 471,981 and €
480,474 over the 9.5-year study period (see calcu-
Table 5. - Lowest and highest direct cost (Euros*) estimated for management of lung cancer (LC) cases during the
9.5 years of study (July 1997- December 2006)
LCs of screening invited cohort LCs of control group
(n=245) (n=243)^
Lowest cost Highest cost Lowest cost Highest cost 
(A): Cost of the screening programme # 390,934 394,042 0,00 0,00
(B): Cost of LC management 2,959,155 3,324,662 2,869,615 3,246,723
[(A)+(B)]: Total cost of screening 3,350,089 3,718,704 2,869,615 3,246,723
and LC management (a) (b) (c) (d)
Incremental cost of LC management 480,474 471,981
including screening (a)-(c) (b)-(d)
Incremental cost of LC management 
including screening (Euros 2012) 618,370 607,440
Incremental cost per one LC death averted 
with screening (Euros 2012) @ 16,273 15,985
LC: lung cancer.
* Costs in the table are in Euros 2002 (the central year of the study), except in the last two lines where the incremental cost
incurred with screening is shown after conversion in Euros 2012 (x 1.287, based on ISTAT healthcare price index).
^ Cost was calculated for 243 cases because 2 cases were estimated to be overdiagnosed (see text).
# Cost of administration, CXRs and false-positives management.
@ A total of 38 LC deaths were averted during the 9.5 years of study.
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lation in table 5). After conversion based on the IS-
TAT healthcare price index, this corresponds to a
total of between € 607,440 and € 618,370 as of
2012 (approx. € 63,941 - € 65,092 per annum).
Accordingly, the incremental costs of LC manage-
ment including screening ranged between €
15,985 and € 16,273 for each of the 38 LC deaths
averted in the cohort.
In conclusion, in a general population of
60,000 adults we carried out an annual CXR
screening program targeted at 5,815 high-risk
smokers, and found that the overall healthcare ex-
pense for LC management including screening in-
creased approximately by € 65,000 per annum.
Discussion
It has long been recognized that LC has better
prognosis when it is incidentally detected during
routine CXR examinations. LCs when incidental-
ly diagnosed are frequently at an early stage and
are resectable, meanwhile symptom-detected cas-
es are predominantly advanced stage cases and
are rarely curable [4-6]. For this reason chest ra-
diograph, a widely accessible and relatively inex-
pensive examination, is intuitively appealing as a
screening tool for early stage LC diagnosis in
subjects with an increased risk of death from LC
such as smokers and former smokers. However,
the numerous randomized trials carried out to
evaluate CXR screening for LC have brought on-
ly mixed results [7-10] and present important
methodological weaknesses [2, 5, 7, 9, 11]. All of
the randomized trials have been criticized due to
a self-selection bias of volunteers [7, 12], and
there still remains uncertainty regarding the value
of LC screening at population level in the real
world [2]. Accordingly the U.S. Preventive Ser-
vices Task Force stated that the evidence provid-
ed, whether it be for or against CXR screening, is
insufficient [13].
Nevertheless, several authors have set out to
develop LC screening programs and cost-effec-
tiveness models with sensitivity analyses [6, 14,
15]. These analyses are quite difficult to interpret.
Models of simulated cohorts have provided highly
variable estimates, ranging from highly cost-effec-
tive to non cost-effective treatment methods [14-
17], and it remains uncertain whether a public
healthcare system can afford the financial burden
of population-based screening for LC.
In 1997 we started a population-based pro-
gramme consisting of annual CXR screenings in
the cohort of high-risk smokers who were identi-
fied within a general population of 60,000 adults
from the Varese province. After the 9.5 year ob-
servation period we subsequently reported that
within the screening-invited cohort, LC mortality
had reduced by 18% [2]. At this point we analyzed
the direct costs of our screening programme. For
the entire cohort of 5,815 screening-invited smok-
ers (21% of whom participated) [12], the incre-
mental cost (as of 2012) of LC management in-
cluding screening was estimated to range between
€ 607,440 and 618,370 (approximately € 65,000
per annum). As 38 fewer LC deaths were record-
ed in the invited cohort, the additional cost of
screening to avoid one LC death (when compared
with no screening and after accounting for over-
diagnosis) was approximately € 16,000. The lat-
ter cost favourably compares with the recently es-
timated $240,000 additional cost of screening
with CT to avert one LC death [6], a ten-fold cost
increase. Our study has limitations. First of all,
cost estimates calculated in 2002 were applied to
the whole period from July 1997 through Decem-
ber 2006. Because 2002 was the central year of
our programme, it is highly unlikely that the over-
all cost of healthcare for all LCs in the study was
markedly either under- or overestimated. Second-
ly, an element of cost was waived in our analysis,
possibly causing screening program costs to be
slightly underestimated: the screening programme
main office was made available free of charge on
NHS premises at the Center for Thoracic Surgery
of University of Insubria, at the Varese Ospedale
di Circolo. A strong feature of this study is the an-
alytical computation based on all costs actually
incurred during screening and LC management in
all individual cases which occurred both within
the invited cohort and the control group in the
NHS setting in Varese. With emphasis of the cur-
rent study being on cost, a complete cost-effec-
tiveness assessment of the screening programme
carried out on smokers remains to be done. How-
ever, the quantification of all the direct costs we
incurred during our population-based CXR
screening programme may be used by health pol-
icy makers to better explore the NHS budget im-
pact and economic sustainability of LC screening.
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